Should I buy or sell OPKO Health stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares. View OPK analyst ratings or view top-rated stocks .

What is OPKO Health's stock price target for 2024?

3 equities research analysts have issued 12-month price targets for OPKO Health's shares. Their OPK share price targets range from $1.50 to $5.40. On average, they anticipate the company's share price to reach $3.73 in the next twelve months. This suggests a possible upside of 205.3% from the stock's current price. View analysts price targets for OPK or view top-rated stocks among Wall Street analysts .

How have OPK shares performed in 2024?

OPKO Health's stock was trading at $1.51 at the beginning of 2024. Since then, OPK shares have decreased by 19.2% and is now trading at $1.22. View the best growth stocks for 2024 here .

When is OPKO Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our OPK earnings forecast .

How were OPKO Health's earnings last quarter?

OPKO Health, Inc. (NASDAQ:OPK) posted its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The biotechnology company earned $181.90 million during the quarter, compared to analysts' expectations of $177.53 million. OPKO Health had a negative trailing twelve-month return on equity of 12.69% and a negative net margin of 21.76%. The firm's revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.11) earnings per share.

What ETFs hold OPKO Health's stock?

ETFs with the largest weight of OPKO Health (NASDAQ:OPK) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) , SPDR S&P Health Care Services ETF (XHS) and Invesco Nasdaq Future Gen 200 ETF (QQQS) . iShares U.S. Healthcare Providers ETF (IHF) .

What is Philip Frost's approval rating as OPKO Health's CEO?

21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com . Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OPKO Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD) , Micron Technology (MU) , NVIDIA (NVDA) , bluebird bio (BLUE) , Gilead Sciences (GILD) , Pfizer (PFE) , Inovio Pharmaceuticals (INO) , Novavax (NVAX) , Advanced Micro Devices (AMD) and AT&T (T) .

Who are OPKO Health's major shareholders?

OPKO Health's stock is owned by many different institutional and retail investors. Top institutional investors include Moseley Investment Management Inc. (0.00%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jane Ph D Hsiao, Jon R Cohen , Opko Health, Inc, Phillip Md Et Al Frost , Richard C Pfenniger Jr, Richard M Krasno, Robert J Shovlin and Steven D Rubin. View institutional ownership trends .

How do I buy shares of OPKO Health?

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OPK

OPKO Health (OPK) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free OPK Stock Alerts

$1.22

-0.02 (-1.22%)

(As of 02:40 PM ET)

Compare

Today's Range: $1.20
▼
$1.25
50-Day Range: $0.87
▼
$1.40
52-Week Range: $0.85
▼
$2.24

Volume: 2.01 million shs
Average Volume: 14.09 million shs
Market Capitalization: $846.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.73

Get OPKO Health alerts:

OPKO Health MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 205.3% Upside
$3.73 Price Target
Short Interest: Healthy
28.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.65
Upright™ Environmental Score
News Sentiment: 0.82
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$5.90 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.33) to ($0.20) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.75 out of 5 stars

Medical Sector

50th out of 930 stocks

Pharmaceutical Preparations Industry

18th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
OPKO Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
OPKO Health has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
28.56% of the float of OPKO Health has been sold short.
Short Interest Ratio / Days to Cover
OPKO Health has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in OPKO Health has recently decreased by 8.37%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OPKO Health does not currently pay a dividend.
Dividend Growth
OPKO Health does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
OPKO Health has received a 66.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Calcifediol", "Diagnostic test kits", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for OPKO Health is -1.65.

2.7

News and Social Media Coverage

News Sentiment
OPKO Health has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for OPKO Health this week, compared to 3 articles on an average week.
Search Interest
Only 48 people have searched for OPK on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.
MarketBeat Follows
43 people have added OPKO Health to their MarketBeat watchlist in the last 30 days. This is an increase of 2% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OPKO Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,903,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
47.26% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.63% of the stock of OPKO Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for OPKO Health are expected to grow in the coming year, from ($0.33) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OPKO Health is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OPKO Health is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OPKO Health has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

About OPKO Health Stock (NASDAQ:OPK)

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

OPK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPK Stock News Headlines

March 19, 2024 | insidertrades.com

Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys 500,000 Shares of Stock

April 6, 2024 | americanbankingnews.com

Equities Analysts Offer Predictions for OPKO Health, Inc.'s Q2 2024 Earnings (NASDAQ:OPK)

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

April 3, 2024 | markets.businessinsider.com

Opko Health Buy Rating Backed by Strategic Asset Sale and Promising Oral Drug Candidate

April 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Opko Health Amid Strategic Divestiture and Operational Improvement Prospects

April 1, 2024 | markets.businessinsider.com

Critical Insights From OPKO Health Analyst Ratings: What You Need To Know

March 29, 2024 | news.yahoo.com

Who else lives on Star Island besides Diddy? Let’s look inside the South Beach enclave

March 28, 2024 | marketwatch.com

OPKO Health Stock Rises 16% After Deal to Sell Assets to Labcorp

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 28, 2024 | marketwatch.com

Labcorp to Buy Some Lab-Testing Businesses From OPKO Health for $237.5 Million

March 28, 2024 | msn.com

Labcorp to buy select assets from OPKO’s BioReference Health

March 28, 2024 | prnewswire.com

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

March 26, 2024 | msn.com

NextPlat expands North American e-commerce business with Outfitter buy

March 16, 2024 | investing.com

Opko Health CEO Phillip Frost buys $444,300 in company stock

March 5, 2024 | globenewswire.com

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

March 4, 2024 | ca.finance.yahoo.com

OPK Mar 2024 0.500 put

March 1, 2024 | finance.yahoo.com

Analysts Have Lowered Expectations For OPKO Health, Inc. (NASDAQ:OPK) After Its Latest Results

February 29, 2024 | finance.yahoo.com

OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript

February 29, 2024 | finance.yahoo.com

OPKO Health Full Year 2023 Earnings: EPS Beats Expectations

February 28, 2024 | finance.yahoo.com

Q4 2023 OPKO Health Inc Earnings Call

February 27, 2024 | msn.com

OPKO Health GAAP EPS of -$0.09 beats by $0.01, revenue of $181.9M beats by $4.37M

February 27, 2024 | finance.yahoo.com

OPKO Health Inc (OPK) Reports Fourth Quarter 2023 Results

February 27, 2024 | globenewswire.com

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

February 27, 2024 | finance.yahoo.com

Insiders hold 50% of OPKO Health, Inc. (NASDAQ:OPK), and they've been buying recently

February 26, 2024 | benzinga.com

OPKO Health's Earnings Outlook

February 22, 2024 | globenewswire.com

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

February 20, 2024 | money.usnews.com

Opko Health Inc

See More Headlines

Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:OPK
CUSIP: 68375N10
CIK: 944809
Web: www.opko.com
Phone: (305) 575-4100
Fax: 305-575-6015
Employees: 3,930
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.73
High Stock Price Target: $5.40
Low Stock Price Target: $1.50
Potential Upside/Downside: +204.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-188,860,000.00
Net Margins: -21.76%
Pretax Margin: -21.35%
Return on Equity: -12.69%
Return on Assets: -8.95%

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 1.55
Quick Ratio: 1.22

Sales & Book Value

Annual Sales: $863.50 million
Price / Sales: 0.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.80 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 696,990,000
Free Float: 367,594,000
Market Cap: $853.81 million
Optionable: Optionable
Beta: 1.81

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Phillip Frost Ph.D. (Age 88)
Chairman & CEO
Comp: $1.45M
Dr. Jane H. Hsiao M.B.A. (Age 77)
Ph.D., Vice Chairman & Chief Technical Officer
Comp: $1.36M
Dr. Elias Adam Zerhouni M.D. (Age 73)
President & Vice Chairman
Comp: $1.36M
Mr. Adam E. Logal (Age 46)
Senior VP, CFO, Chief Accounting Officer & Treasurer
Comp: $1.09M
Mr. Steven D. Rubin Esq. (Age 64)
J.D., Executive VP of Administration & Director
Comp: $1.22M
Dr. Akhtar Ashfaq FACP
FASN, M.D., Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal
Dr. Gary J. Nabel M.D. (Age 69)
Ph.D., Chief Innovation Officer & Director
Dr. Charles W. Bishop (Age 72)
Chief Executive Officer of OPKO Renal
Dr. Antonio F. Cruz (Age 71)
President of Transition Therapeutics
Mr. Hans Berner
President of OPKO Health Iberoamerica

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OPK Stock Analysis - Frequently Asked Questions

Should I buy or sell OPKO Health stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares.
View OPK analyst ratings or view top-rated stocks.
What is OPKO Health's stock price target for 2024?: 3 equities research analysts have issued 12-month price targets for OPKO Health's shares. Their OPK share price targets range from $1.50 to $5.40. On average, they anticipate the company's share price to reach $3.73 in the next twelve months. This suggests a possible upside of 205.3% from the stock's current price.
View analysts price targets for OPK or view top-rated stocks among Wall Street analysts.
How have OPK shares performed in 2024?: OPKO Health's stock was trading at $1.51 at the beginning of 2024. Since then, OPK shares have decreased by 19.2% and is now trading at $1.22.
View the best growth stocks for 2024 here.
When is OPKO Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our OPK earnings forecast.
How were OPKO Health's earnings last quarter?: OPKO Health, Inc. (NASDAQ:OPK) posted its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). The biotechnology company earned $181.90 million during the quarter, compared to analysts' expectations of $177.53 million. OPKO Health had a negative trailing twelve-month return on equity of 12.69% and a negative net margin of 21.76%. The firm's revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.11) earnings per share.
What ETFs hold OPKO Health's stock?: ETFs with the largest weight of OPKO Health (NASDAQ:OPK) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), SPDR S&P Health Care Services ETF (XHS) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Healthcare Providers ETF (IHF).

What is Philip Frost's approval rating as OPKO Health's CEO?: 21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of OPKO Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T).
Who are OPKO Health's major shareholders?: OPKO Health's stock is owned by many different institutional and retail investors. Top institutional investors include Moseley Investment Management Inc. (0.00%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jane Ph D Hsiao, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Richard M Krasno, Robert J Shovlin and Steven D Rubin.
View institutional ownership trends.
How do I buy shares of OPKO Health?: Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPK) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial